Strata Critical Medical Charts a New Course in Medical Logistics

Following a decisive strategic pivot, the company formerly known as Blade Air Mobility has completed its reinvention. Now operating as Strata Critical Medical, Inc., the firm has fully exited the passenger transport sector to concentrate exclusively on the critical medical logistics market. This transformation, marked by a new corporate identity, a fresh Nasdaq ticker symbol, and enhanced leadership, positions the company to capitalize on a specialized niche.

The company's latest financial results, reported prior to its rebranding, underscore the strength of its core medical division. For the second quarter of 2025, Blade Air Mobility posted total revenue of $70.8 million, representing a 4.2% increase. Significantly, revenue from the medical segment—now the company's sole focus—surged 17.6% to $45.1 million. The quarterly net loss was reduced to $3.7 million.

As of the end of that quarter, the company's balance sheet showed $113.4 million in cash and short-term investments. Looking ahead, management has provided revenue guidance for fiscal year 2026, projecting it to fall between $255 million and $270 million. On December 3, the company's shares traded at $4.44. Market researchers covering the equity have issued an average "Buy" recommendation with a price target of $6.50.

Should investors sell immediately? Or is it worth buying Blade Air Mobility?

A Strategic Shift Executed

The fundamental restructuring was cemented by the sale of the entire passenger business unit to Joby Aviation for up to $125 million. This move provided the capital and strategic clarity to dedicate all resources to the medical logistics operation. The transaction, which also granted Joby access to Blade's urban air mobility infrastructure, was finalized ahead of the company's debut on the Nasdaq Capital Market under its new name and the ticker "SRTA" on August 29, 2025.

Leadership Strengthened for Growth

To drive its focused strategy forward, Strata Critical Medical appointed healthcare veteran Will Cook to its board of directors on December 3, 2025. Cook brings extensive experience from roles including Chief Executive Officer of Vail Health and leadership positions at UPMC and Johns Hopkins. His appointment signals the company's commitment to expanding its national platform for organ recovery and logistics, as well as developing new service lines within the medical sector.